In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Domantis and Peptech announce second domain antibody deal
Abbott and Domantis establish collaboration
Domantis licenses domain antibody technology
Abbott and Domantis In Antibody Technology License Deal
Domantis licenses exclusive rights from the Medical Research Council
EVOGENIX RECEIVES COURT ORDER REGARDING MERGER WITH PEPTECH
Peptech executes licence agreement with Centocor
GlaxoSmithKline to acquire Domantis for 230 million
DOMANTIS ANNOUNCES ALLIANCE TO DISCOVER DOMAIN ANTIBODIES FOR AUTOIMMUNE DISEASES